Literature DB >> 2808213

Meropenem: evidence of lack of proconvulsive tendency in mice.

J B Patel1, R E Giles.   

Abstract

The proconvulsive tendency of the novel carbapenem, meropenem was compared to that of imipenem, alone and in combination with cilastatin. The potentiation of metrazole-induced convulsions in mice was measured. Both imipenem and imipenem/cilastatin caused significant potentiation of metrazole-induced convulsions at a dose of 200 mg/kg, i.v. In contrast, meropenem (50-400 mg/kg, iv) failed to exhibit any significant potentiation of metrazole-induced seizures.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2808213     DOI: 10.1093/jac/24.suppl_a.307

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

1.  Pharmacokinetic-pharmacodynamic modeling of the electroencephalogram effect of imipenem in healthy rats.

Authors:  A Dupuis; W Couet; J Paquereau; S Debarre; A Portron; C Jamois; S Bouquet
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.

Authors:  B A Christensson; I Nilsson-Ehle; M Hutchison; S J Haworth; B Oqvist; S R Norrby
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 3.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

4.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

Review 5.  Neurotoxicity of carbapenem antibacterials.

Authors:  S R Norrby
Journal:  Drug Saf       Date:  1996-08       Impact factor: 5.606

6.  Meropenem versus imipenem/cilastatin in the treatment of intraabdominal infections requiring surgery.

Authors:  K Kanellakopoulou; H Giamarellou; P Papadothomakos; H Tsipras; J Chloroyiannis; R Theakou; P Sfikakis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-06       Impact factor: 3.267

7.  Prospective, randomised, multicentre study of meropenem versus imipenem/cilastatin as empiric monotherapy in severe nosocomial infections.

Authors:  J Garau; J Blanquer; L Cobo; S Corcia; M Daguerre; F J de Latorre; C León; F Del Nogal; A Net; J Rello
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 3.267

8.  Relationship between structure and convulsant properties of some beta-lactam antibiotics following intracerebroventricular microinjection in rats.

Authors:  A De Sarro; D Ammendola; M Zappala; S Grasso; G B De Sarro
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 9.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

10.  Randomized comparison of meropenem with cefotaxime for treatment of bacterial meningitis. Meropenem Meningitis Study Group.

Authors:  K P Klugman; R Dagan
Journal:  Antimicrob Agents Chemother       Date:  1995-05       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.